一、获奖

（1）南京药学会2018年度科学技术一等奖，R3

（2）江苏省2018年度江苏省医学新技术引进二等奖，R3

二、代表性论著

[1] Zhang, X.*; Cai, X.; Zheng, X.*, Gut microbiome-oriented therapy for metabolic diseases: challenges and opportunities towards clinical translation. Trends Pharmacol Sci 2021, 42(12):984-987. (IF 14.819 )

[2] Zhang, X.*; Zhao, Y.; Shao, H.; Zheng, X.*, Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes. Psychoneuroendocrinology 2019, 108, 163-171. (IF 4.905)

[3] Zhang, X.*; Zhao, Y.; Liu, Y.; Yuan, Y.; Shao, H.; Zheng, X.*, Regulation of obesity-associated metabolic disturbance by the antipsychotic drug olanzapine: Role of the autophagy-lysosome pathway. Biochem Pharmacol 2018, 158, 114-125. (IF 5.858)

[4] Zhang, X.*; Zhao, Y.; Chen, S.; Shao, H.*, Anti-diabetic drugs and sarcopenia: emerging links mechanistic insights, and clinical implications. J Cachexia Sarcopeni 2021, 12(6):1368-1379. (IF 12.910 )

[5] Zhang, X.*; Shao, H.; Zheng, X.*, Amino acids at the intersection of nutrition and insulin sensitivity. Drug Discov Today 2019, 24 (4), 1038-1043. (IF 7.851)

[6] Zhang, X.; Liu, Y.; Shao, H.; Zheng, X.*, Obesity Paradox in Lung Cancer Prognosis: Evolving Biological Insights and Clinical Implications. J Thorac Oncol 2017, 12 (10), 1478-1488. (IF 15.609)

[7] Yang, J.#; Zhang, X.#; Yuan, P.; Xu, Y.; Grutzendler, J.; Shao, Y.; Moore, A.*; Ran, C.*, Oxalate-curcumin-based probe for micro- and macroimaging of reactive oxygen species in Alzheimer's disease. Proc Natl Acad Sci U S A 2017, 114 (47), 12384-12389. (IF 9.412)

[8] Yang, J.#; Zhang, X.#; Zhu, Y.; Lenczowski, E.; Tian, Y.; Zhang, C.;  Hardt, M.;  Qiao, C.;  Tanzi, R. E.;  Moore, A.;  Ye, H.; Ran, C.*, The double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants. Chem Sci 2017, 8 (9), 6155-6164. (IF 9.825)

[9] Zhang, X.; Guo, F.; Shao, H.*; Zheng, X.*, Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities. J Infect 2017, 74 (2), 118-130. (IF 6.072)

[10] Zhang, X.*; Zheng, X.*; Yuan, Y., Treatment of insulin resistance: straight from the gut. Drug Discov Today 2016, 21 (8), 1284-90. (IF 7.851)

[11] Zhang, X.#; Tian, Y.#; Zhang, C.; Tian, X.; Ross, A. W.; Moir, R. D.; Sun, H.; Tanzi, R. E.;  Moore, A.*; Ran, C.*, Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. Proc Natl Acad Sci U S A 2015, 112 (31), 9734-9. (IF 9.412)

[12] Zhang, X., Tian, Y., Yuan, P., Li, Y., Yaseen, M. A., Grutzendler, J., Moore, A.*, Ran, C.*, A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease. Chem Commun (Camb) 2014, 50 (78), 11550-3. (IF 6.222)

[13] Zhang, X., Tian, Y., Li, Z., Tian, X., Sun, H., Liu, H., Moore, A.*, Ran, C.*, Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. J Am Chem Soc 2013, 135 (44), 16397-409. (IF 15.419)